Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
AML
•
Hematology
Is there data for the ideal number of consolidation cycles in patients older than 60 with favorable risk AML?
Related Questions
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
How would you manage an elderly patient with mild pancytopenia who refuses bone marrow biopsy and whose flow cytometry is suggestive of CMML/MDS?
Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
For AML patients, when do you stop antiinfective agents?
With the recent approval of quizartinib, what is your preferred first-line FLT3 inhibitor in combination with chemotherapy for a fit AML patient with a FLT3-ITD mutation?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
